Danaher Corp (DHR) Stock AnalysisDHRDanaher Corp

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services. The Company also provides pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).

Danaher Corp is a good buy right now due to its current price of $229.04 being below analyst price targets, which range from $240 to $255. Additionally, the forward P/E ratio of 23.81 indicates reasonable valuation relative to expected earnings growth. The recent partnership with NVIDIA to enhance AI in scientific instruments could drive future revenue growth, despite a year-to-date decline of 0.59%. The main risk is the potential for a 5% market pullback by year-end, as indicated by market analysts.

17 analysts cover DHR: 13 rate it Buy, 4 Hold and 0 Sell. The average price target is 266.18.